Sat.Jan 09, 2021 - Fri.Jan 15, 2021

Ten key clinical trials to watch in the first half of 2021

Bio Pharma Dive

Study results could come soon for several coronavirus vaccines, as well as experimental medicines from Amgen, Vertex and Sage Therapeutics

Help Wanted: New breed of pharma CEOs

World of DTC Marketing

SUMMARY: The argument that the first rule of business is to make money is becoming more irrelevant in a time of social chaos. Every company is entitled to make a profit, but when a CEO earns $28 million a year, and can’t afford medications, something is dreadfully wrong.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Navigating the Global NHP Shortage: How to Keep Your Development Program on Track


In the first half of 2020 and as a direct consequence of the ongoing pandemic, China issued a ban on the export of non-human primates (NHPs) , including those used for pharmaceutical research.

Ukraine genome survey adds missing pieces to human diversity puzzle


International Ukraine Genetic Diversity Project finds a quarter of the genetic variation in Europe, dramatically increasing information on population diversity and medical genetic variation Credit: Oakland University Today, the largest study of genetic diversity in Ukraine was published in the open science journal GigaScience.

BioMarin tries to get hemophilia gene therapy back on track with positive data

Bio Pharma Dive

Full one-year results from a Phase 3 study show the therapy, known as Roctavian, sharply reduced bleeds and use of blood-clotting treatments

Pharma agency babble

World of DTC Marketing

HEY NOW: If you want a great example of why pharma needs to build expertise in-house and rely less on agencies, read the newest white paper from Intouch Group. I read the whitepaper, and it was full of vague obscurities that are, frankly, embarrassing. Want a great example of agency babble?

Sales 153

Parkinson’s Disease: How close are we to a cure?


Neurological disorders are the leading source of disability globally, and Parkinson’s is the fastest-growing neurological condition.

More Trending

5 trends in biotech dealmaking to watch in 2021

Bio Pharma Dive

Brain drugs, private equity players and blank-check companies are just some of the things deal experts say they'll be keeping an eye on this year

Drugs 242

Pharma: The time is now for digital marketing

World of DTC Marketing

SUMMARY : Digital marketing is not a tactic. It’s a mindset. With the changes to healthcare on the horizon, the time has come to start building digital capabilities in all areas of company functions.

Alzheimer’s Drug Shows Promise in Small Trial

NY Times

Participants with the disease still declined, but much more slowly than those receiving a placebo, investigators say. Alzheimer's Disease Clinical Trials Drugs (Pharmaceuticals) Brain Eli Lilly and Company donanemab

Trials 114

Honeybees reveal how our floral landscape has changed over the last 65 years


Honeybees have been helping researchers from the National Botanic Garden of Wales track how the UK’s fields, hedgerows, wild spaces and gardens have changed since the 1950s.

Dana-Farber launches venture fund targeting incurable cancers

Bio Pharma Dive

Binney Street Capital plans to invest in eight to 10 companies over the next three years. Developing new drugs will be a core focus, though investments could also go toward health services, digital health or diagnostics

Drugs 229

A huge online health opportunity

World of DTC Marketing

KEY POINTS: The social media shutdown of far-right hate groups and speech is once again spotlighting freedom of speech issues. Whose responsibility is it to ensure that health information, for example, online is accurate and doesn’t lead to bad patient decisions?

Neurology’s Growing Need for Disposable Technologies

Pharma Mirror

By Boris Goldstein, Co-Founder & Executive Chairman at Brain Scientific COVID-19 is known for its impacts on a patient’s respiratory system, but it has also been found to affect individuals in unique ways and with varying severity levels depending on their age, risk factors, and comorbidities.

Astronomers document the rise and fall of a rarely observed stellar dance


Credit: Space Telescope Science Institute The sun is the only star in our system. But many of the points of light in our night sky are not as lonely. By some estimates, more than three-quarters of all stars exist as binaries — with one companion — or in even more complex relationships.

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days

DTC for small, older, patient populations

World of DTC Marketing

SUMMARY: TV doesn’t make sense for smaller and older patient populations. DTC marketers should be thinking digital and aligning execution with their needs. BMS has been advertising Opdivo via DTC TV ads but does TV really make sense?

Drugs 152

NeuroRx on the Move: An Interview with Founder and CEO Jonathan Javitt


Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx


Scientists modeled protein behavior of archaeal viruses to crack protein folding mystery


Credit: FEFU press office Scientists from the Pacific Quantum Center of Far Eastern Federal University (FEFU) figured out how the AFV3-109 protein with slipknot structure folds and unfolds depending on temperature.

Analysis of success metrics from a risk-based quality management (RBQM) approach to clinical trial management

Bio Pharma Dive

Gain increased study efficiency and quality with risk-based quality management

Boehringer Ingelheim announces partnership with Google

Pharma Times

Partnership will aim to research and implement quantum computing in pharma R&D

New Study Shows COVID-19 Immunity Can Last at Least Eight Months After Infection


Evidence continues to build for long-lasting immunity to COVID-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms

Conductive nature in crystal structures revealed at magnification of 10 million times


University of Minnesota study opens up possibilities for new transparent materials that conduct electricity Credit: Mkhoyan Group, University of Minnesota In groundbreaking materials research, a team led by University of Minnesota Professor K.

PQE Group creates an internal research task force to fight the spread of misinformation in relation to COVID-19

Bio Pharma Dive

PQE Group creates internal task force to fight the biggest side effect of the Covid-19 pandemic: the infodemic. A common vocabulary to reinforce knowledge, security and safety

Synairgen begins large-scale trial of inhaled COVID-19 treatment

Pharma Times

First patient in global trial dosed in the UK

New COVID-19 Mutation Could Mess Up Tests, Trigger False Negatives


On Friday, the U.S. Food and Drug Administration (FDA) issued an official alert stating that it could trigger false negatives in COVID-19 tests

Drugs 100

First human culture lasted 20,000 years longer than thought


5 questions facing the FDA in 2021

Bio Pharma Dive

A new commissioner, high-stakes coronavirus vaccine reviews and a rising gene therapy workload will test the agency this year

Supreme Court Revives Abortion-Pill Restriction

NY Times

In their first abortion case since Justice Amy Coney Barrett joined the court, the justices reinstated a requirement that women seeking medication abortions pick up a pill in person.

Drugs 97

Umbilical Cord Stem Cells Show Promise as COVID-19 Therapy


Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in COVID-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers

Expanding the biosynthetic pathway via retrobiosynthesis


Researchers reports a new strategy for the microbial production of multiple short-chain primary amines via retrobiosynthesis Credit: KAIST KAIST metabolic engineers presented the bio-based production of multiple short-chain primary amines that have a wide range of applications in chemical industries for the first time.

Lilly rockets up on mixed Alzheimer's results

Bio Pharma Dive

Analysts cautioned that results for Lilly's drug, donanemab, weren't a total home run. Even so, investors sent the company's market value higher by roughly $18 billion

UCB backs epilepsy-focused digital heath startup Nile AI

Pharma Phorum

Belgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing new projects. One of those is now being launched as a new company – Nile AI – that aims to improve the care of people with epilepsy.

Sales 91

Needle-free COVID-19 vaccine COVI-VAC enters Phase 1 trials

BioPharma Reporter

Codagenixâs intranasal COVID-19 vaccine has entered Phase 1 clinical trials: with the first volunteers dosed in the UK. Bio Developments

Rapid blood test identifies COVID-19 patients at high risk of severe disease


DNA 72

JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining

Bio Pharma Dive

Biogen faces a crucial FDA decision on its Alzheimer’s drug aducanumab, while Vertex gets used to investor pressure to do a deal. Sarepta, meanwhile, is picking up the pieces after a disappointing gene therapy readout

J&J single-shot COVID-19 vaccine shows early promise

Pharma Phorum

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month.